Cordycepin inhibits myogenesis via activating the ERK1/2 MAPK signalling pathway in C2C12 cells

Biomed Pharmacother. 2023 Sep:165:115163. doi: 10.1016/j.biopha.2023.115163. Epub 2023 Jul 14.

Abstract

Cordycepin (with a molecular formula of C10H13N5O3), a natural adenosine isolated from Cordyceps militaris, has an important regulatory effect on skeletal muscle remodelling and quality maintenance. The aim of this study was to investigate the effect of cordycepin on myoblast differentiation and explore the underlying molecular mechanisms of this effect. Our results showed that cordycepin inhibited myogenesis by downregulating myogenic differentiation (MyoD) and myogenin (MyoG), preserved undifferentiated reserve cell pools by upregulating myogenic factor 5 (Myf5) and retinoblastoma-like protein p130 (p130), and enhanced energy reserves by decreasing intracellular reactive oxygen species (ROS) and enhancing mitochondrial membrane potential, mitochondrial mass, and ATP content. The effect of cordycepin on myogenesis was associated with increased phosphorylation of extracellular signal-regulated kinase 1/2 (p-ERK1/2). PD98059 (a specific inhibitor of p-ERK1/2) attenuated the inhibitory effect of cordycepin on C2C12 differentiation. The present study reveals that cordycepin inhibits myogenesis through ERK1/2 MAPK signalling activation accompanied by an increase in skeletal muscle energy reserves and improving skeletal muscle oxidative stress, which may have implications for its further application for the prevention and treatment of degenerative muscle diseases caused by the depletion of depleted muscle stem cells.

Keywords: C2C12 cells; Cordycepin; ERK1/2 MAPK; Myogenesis; Reserve cell.

MeSH terms

  • Cell Differentiation
  • Deoxyadenosines* / pharmacology
  • MAP Kinase Signaling System*
  • Muscle Development

Substances

  • cordycepin
  • Deoxyadenosines